schizophrenia treatment

Johnson & Johnson's New Brunswick corporate campus
Apr 28, 2026

FDA approves J&J’s Caplyta to prevent schizophrenia relapse

The FDA approved Johnson & Johnson’s Caplyta to prevent schizophrenia relapse, expanding its use after trial data showed reduced risk.